Fairshake affiliates spend about $3.1 million on advertising to support Adrian Boafo in the Democratic primary
Foresight News reported, citing crypto journalist Eleanor Terrett, that Protect Progress, an affiliate of the cryptocurrency political action committee Fairshake, has spent approximately $3.1 million on advertising in Maryland's 5th Congressional District in support of State Representative Adrian Boafo's campaign in the Democratic primary. According to the latest data from the independent polling firm Clarity Campaign Labs, commissioned by Fairshake, Boafo is currently leading the primary with 17% support, a significant increase from the mid-April baseline poll (10%) and before the organization's involvement at the beginning of the year (3%).
Previously, Protect Progress completed several successful political investments in the Texas primary runoff. Boafo has also received endorsements from Maryland Senator Angela Alsobrooks and Governor Wes Moore, and holds the highest favorability among all primary candidates, reaching 40%.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Forex Today: US flash Consumer Sentiment and Canadian jobs in the limelight
Malaysian Ringgit: Fiscal anchor case – MUFG
Nasdaq Drops Over 300 Points After OpenAI's Revenue Comes In $20 Billion Short
BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data
On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)
Crypto prices
More
